SLC5A2 and type 2 diabetes mellitus: In this meta-analysis, we investigated the impact of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes mellitus, according to large-scale cardiovascular outcome trials.